Table 3.
Modified Localized Scleroderma Skin Severity Index (mLoSSI) and physician global assessment-activity (PGA-A) scores for baseline and followup visits.
| Visit | ||||||||
|---|---|---|---|---|---|---|---|---|
| V1 | V2 | V3 | V4 | V5 | V6 | V7 | V8 | |
| Months from initial visit | ||||||||
| Mean (SD) | 0 | 1.3 (1.2) | 2.6(1.8) | 4.1 (2.3) | 6.1(2.9) | 8.5 (3.5) | 11.5(4.7) | 13.8 (4.3) |
| mLoSSI | ||||||||
| Median | 8 | 3 | 2 | 1 | 1 | 0 | 0 | 0 |
| IQR | 4–15 | 1–5 | 0–4 | 0–2 | 0–2 | 0–1 | 0–1 | 0–1 |
| Range | 2–44 | 0–12 | 0–13 | 0–11 | 0–12 | 0–11 | 0–8 | 0–9 |
| New lesion | ||||||||
| Median | 0 | — | — | — | — | — | — | — |
| IQR | 0–3 | — | — | — | — | — | — | — |
| Range | 0–15 | — | — | — | — | — | — | — |
| Enlarged | ||||||||
| Median | 0 | — | — | — | — | — | — | — |
| IQR | 0–3 | — | — | — | — | — | — | — |
| Range | 0–9 | — | — | — | — | — | — | — |
| Erythema | ||||||||
| Median | 3 | 1 | 0 | 0 | — | — | — | — |
| IQR | 1–5 | 0–1 | 0–0 | 0–0 | — | — | — | — |
| Range | 0–6 | 0–6 | 0–3 | 0–1 | — | — | — | — |
| Skin thickness | ||||||||
| Median | 2 | 2 | 1 | 1 | 1 | 0 | 0 | 0 |
| IQR | 0–5 | 0–4 | 0–3 | 0–2 | 0–1 | 0–1 | 0–1 | 0–1 |
| Range | 0–12 | 0–12 | 0–12 | 0–11 | 0–11 | 0–11 | 0–9 | 0–8 |
| PGA-A* | ||||||||
| Median | 61 | 22 | 8 | 2 | 1 | 0 | 0 | 0 |
| IQR | 36–82 | 13–60 | 1–32 | 0–24 | 0–20 | 0–6 | 0–4 | 0–0 |
| Range | 7–97 | 0–84 | 0–78 | 0–68 | 0–37 | 0–36 | 0–38 | 0–9 |
*
n = 27 for complete PGA-A. The change in median mLoSSI, its components (new lesion, enlargement of lesion, erythema, and skin thickness), and PGA-A activity are described at each visit since the initiation of systemic therapy regimen. New lesion and enlarged lesion components are scored as either 0 (none) or 3 (present), while erythema and skin thickness components are scored 0–3 (mild-moderate-severe) per anatomic site. IQR: interquartile range.